Product Description
a phosphodiesterase type 4 (PDE4) inhibitor, for the treatment of tuberculosis (TB) and erythema nodosum leprosum (ENL), an inflammatory cutaneous and systemic complication of leprosy. AMG 634 could have potential for patients suffering from ENL and TB, two diseases that continue to challenge many countries around the world (Sourced from: https://www.amgen.com/newsroom/press-releases/2020/06/amgen-is-supporting-advancement-of-amg-634-for-global-health-diseases-in-developing-countries)
Mechanisms of Action: PDE4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Tuberculosis, Pulmonary|Leprosy|Erythema Nodosum|Lupus Erythematosus, Cutaneous|Lupus Erythematosus, Systemic|Lupus Erythematosus, Discoid
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| DRTB-HDT | P2 |
Unknown status |
Tuberculosis, Pulmonary |
2027-09-08 |
2025-05-06 |
Treatments |
|
| AUR1-1-313 DRTB-HDT | P2 |
Not yet recruiting |
Tuberculosis, Pulmonary |
2025-12-31 |
2025-05-02 |
Treatments |
|
| Nepal CC-11050 | P2 |
Unknown status |
Erythema Nodosum|Leprosy |
2021-03-30 |
2025-01-03 |
Primary Endpoints|Treatments|Trial Status |
|
| CC-11050-CP-010 | P1 |
Completed |
Healthy Volunteers |
2020-02-27 |
50% |
2020-06-23 |
Primary Endpoints|Treatments |
| CC-11050-CLE-002 | P2 |
Completed |
Lupus Erythematosus, Discoid|Lupus Erythematosus, Cutaneous|Lupus Erythematosus, Systemic |
2013-01-01 |
2020-06-25 |
Primary Endpoints|Treatments |